BENIGN MARROW PROGENITORS ARE ENRICHED IN THE CD34(+)/HLA-DR(LO) POPULATION BUT NOT IN THE CD34(+)/CD38(LO) POPULATION IN CHRONIC MYELOID-LEUKEMIA - AN ANALYSIS USING INTERPHASE FLUORESCENCE IN-SITU HYBRIDIZATION

被引:57
作者
KIRK, JA
REEMS, JA
ROECKLEIN, BA
VANDEVANTER, DR
BRYANT, EM
RADICH, J
EDMANDS, S
LEE, A
TOROKSTORB, B
机构
[1] FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA
[2] SWEDISH MED CTR, MED CTR, INST TUMOR, SEATTLE, WA USA
关键词
D O I
10.1182/blood.V86.2.737.bloodjournal862737
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fluorescence in situ hybridization (FISH) was used to discriminate between benign and malignant cells in sorted populations of chronic myelogenous leukemia (CML) marrow. FISH has the advantage of allowing for a cell by cell analysis of the breakpoint cluster region (BCR) gene rearrangement immediately after flow sorting in nondividing G(0)/G(1) cells that are potentially transcriptionally inactive., We initially selected CD34(+) cells with very low expression of the activation antigen CD38 as a candidate phenotype for an immature and hypothetically more benign cell population, but found no enrichment for Ph negativity in that subtype. In five CML samples, 55% +/- 3.3% (mean +/- SE) of CD34(+)/CD38h(hi) cells had the BCR gene rearrangement, similar to 57% +/- 3.7% seen in the CD34(+)/CD381(lo) population. In contrast, subsequent experiments (n = 4) determined that the CD34(+)/HLA-DR(lo) population in CML marrow does contain an increased proportion of benign cells: 15% +/- 1% of the CD34(+)/DR(lo) cells were BCR rearranged, compared with 52% +/- 5.8% of the CD34(+)/DR(hi) cells (P =.001). Our results indicate that benign progenitors in CML are enriched within the CD34(+) cells with low DR antigen expression, but not low CD38 expression, One possible interpretation of these observations is that low CD38 antigen expression is not as useful as low HLA-DR expression for isolating immature cells. (C) 1995 by The American Society of Hematology.
引用
收藏
页码:737 / 743
页数:7
相关论文
共 29 条
[1]   DETECTION OF THE PHILADELPHIA-CHROMOSOME IN INTERPHASE NUCLEI [J].
ARNOLDUS, EPJ ;
WIEGANT, J ;
NOORDERMEER, IA ;
WESSELS, JW ;
BEVERSTOCK, GC ;
GROSVELD, GC ;
VANDERPLOEG, M ;
RAAP, AK .
CYTOGENETICS AND CELL GENETICS, 1990, 54 (3-4) :108-&
[2]  
BARNETT MJ, 1994, BLOOD, V84, P724
[3]  
BEDI A, 1993, BLOOD, V81, P2898
[4]   GENE-MARKING TO TRACE ORIGIN OF RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
BRENNER, MK ;
RILL, DR ;
MOEN, RC ;
KRANCE, RA ;
MIRRO, J ;
ANDERSON, WF ;
IHLE, JN .
LANCET, 1993, 341 (8837) :85-86
[5]   LONG-TERM MARROW CULTURE REVEALS CHROMOSOMALLY NORMAL HEMATOPOIETIC PROGENITOR CELLS IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA [J].
COULOMBEL, L ;
KALOUSEK, DK ;
EAVES, CJ ;
GUPTA, CM ;
EAVES, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (25) :1493-1498
[6]  
EDMANDS S, 1994, PCR METH APPL, V3, P317
[7]  
ENTZ M, 1994, BLOOD, V83, P1922
[8]   EVIDENCE FOR A MULTISTEP PATHOGENESIS OF CHRONIC MYELOGENOUS LEUKEMIA [J].
FIALKOW, PJ ;
MARTIN, PJ ;
NAJFELD, V ;
PENFOLD, GK ;
JACOBSON, RJ ;
HANSEN, JA .
BLOOD, 1981, 58 (01) :158-163
[9]   LOCALIZATION OF THE C-ABL ONCOGENE ADJACENT TO A TRANSLOCATION BREAK POINT IN CHRONIC MYELOCYTIC-LEUKEMIA [J].
HEISTERKAMP, N ;
STEPHENSON, JR ;
GROFFEN, J ;
HANSEN, PF ;
DEKLEIN, A ;
BARTRAM, CR ;
GROSVELD, G .
NATURE, 1983, 306 (5940) :239-242
[10]  
KANTARJIAN HM, 1993, BLOOD, V82, P691